^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NDRG1-H

    i
    Other names: NDRG1, N-Myc Downstream Regulated 1, Reducing Agents And Tunicamycin-Responsive Protein, N-Myc Downstream-Regulated Gene 1 Protein, Nickel-Specific Induction Protein Cap43, Differentiation-Related Gene 1 Protein, Protein NDRG1, CAP43, DRG-1, NDR1, TDD5, Protein Regulated By Oxygen-1, PROXY1, CMT4D, HMSNL, RIT42, TARG1, NMSL
    Entrez ID:
    10397
    Related biomarkers:
    Expression
    Associations

    News

    Trials
    21d
    High Expression of NDRG1 is a Poor Prognostic Factor in Patients with Endometrial Endometrioid Carcinoma with Long-Term Observation. (PubMed, Kurume Med J)
    High expression of NDRG1 was also correlated with high levels of angiogenesis and low expression of the estrogen receptor. These results suggest that high expression of NDRG1 is associated with angiogenesis and is an indicator of a poor prognosis in women with EEC.
    Journal
    |
    ER (Estrogen receptor) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • NDRG1 (N-Myc Downstream Regulated 1)
    |
    ER expression • NDRG1-H
    1year
    N-Myc Downstream Regulated Gene-1 May Play an Important Role in the Prognosis of Ovarian Cancer, in Its Association with Beta-Catenin. (PubMed, Kurume Med J)
    The Kaplan-Meier analysis showed a significant association between the NDRG1 expression level and progression-free survival: high NDRG1 expression was related to poor survival. Our results suggest that the increased expression of NDRG1 is associated with cell adhesion and may be a poor prognostic indicator in women with ovarian cancer.
    Retrospective data • Journal
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • NDRG1 (N-Myc Downstream Regulated 1)
    |
    CDH1 expression • CTNNB1 expression • NDRG1-H
    3years
    NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. (PubMed, J Natl Cancer Inst)
    We demonstrated that NDRG1 drives tumor progression and brain metastasis in aggressive breast cancers and that NDRG1-high expression correlates with worse clinical outcomes, suggesting that NDRG1 may serve as a therapeutic target and prognostic biomarker in aggressive breast cancers.
    Journal
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • NDRG1 (N-Myc Downstream Regulated 1)
    |
    NDRG1-H
    3years
    NDRG1 expression is an independent prognostic factor in inflammatory breast cancer (SABCS 2021)
    Our findings demonstrated that NDRG1 is positively correlated with aggressive tumor characteristics in IBC and that it is an independent prognostic factor for OS and DSS in IBC patients, suggesting that targeting NDRG1 may provide a novel therapeutic strategy to improve outcomes for patients with IBC. Our data further suggests that NDRG1 warrants further investigation in radiation response.
    ER (Estrogen receptor) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • NDRG1 (N-Myc Downstream Regulated 1)
    |
    ER negative • NDRG1-H